Skip to content

CERO THERAPEUTICS HOLDINGS, INC.: 10-Q filed 2023-08-14

What CERO THERAPEUTICS HOLDINGS, INC. reported in its quarterly report filed 2023-08-14 (fiscal Q2 2023): 15 published measures, 44 facts as tagged in accession 0001213900-23-066987.

This filing

Form
10-Q (quarterly report)
Filed
2023-08-14
Fiscal period
fiscal Q2 2023
Accession
0001213900-23-066987 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CERO THERAPEUTICS HOLDINGS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-06-3014,110,263USD
At 2022-12-3142,367,032USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-06-3013,561,017USD
At 2022-12-3139,898,341USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-06-30-13,291,394USD
At 2023-03-31-11,578,660USD
At 2022-12-31-11,000,154USD
At 2022-06-30-8,159,431USD
At 2022-03-31-8,047,862USD
At 2021-12-31-7,669,865USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-1,437,733USD91
2023-01-01 to 2023-06-30-1,919,445USD181
2023-01-01 to 2023-03-31-481,712USD90
2022-04-01 to 2022-06-30-111,569USD91
2022-01-01 to 2022-06-30-489,566USD181
2022-01-01 to 2022-03-31-377,997USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-1,080,872USD181
2022-01-01 to 2022-06-30-544,798USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-01-01 to 2023-06-30525,000USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-01-01 to 2023-06-30185,236USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-06-30-13,291,941USD
At 2022-12-31-11,000,701USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2023-04-01 to 2023-06-3044,658USD91
2023-01-01 to 2023-06-3044,658USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-1,543,578USD91
2023-01-01 to 2023-06-30-2,133,846USD181
2022-04-01 to 2022-06-30-376,580USD91
2022-01-01 to 2022-06-30-781,357USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-06-304,411,017USD
At 2022-12-3130,748,341USD

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-06-30105,234USD
At 2022-12-31475,870USD
At 2022-06-30553,775USD
At 2021-12-311,098,573USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2023-06-30107,979USD
At 2022-12-31225,188USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-1,393,075USD91
2023-01-01 to 2023-06-30-1,874,787USD181
2022-04-01 to 2022-06-30-111,569USD91
2022-01-01 to 2022-06-30-489,566USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-301,520,878USD91
2023-01-01 to 2023-06-302,087,446USD181
2022-04-01 to 2022-06-30326,580USD91
2022-01-01 to 2022-06-30681,357USD181

Inspect the source

Entity
CERO THERAPEUTICS HOLDINGS, INC. / CIK 0001870404
Captured
2026-09-19T11:21:59.403Z
SEC response SHA-256
8c8c2bd97bf9d18c6c5d6af2474c4302fa2e6a98d7edbc511d62e8f44742c0ac

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001870404.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))